Table 3 Traditional preventive treatment patterns in OVERCOME (EU) migraine cohort and in survey respondents eligible for migraine preventive medication (excluding calcitonin gene-related peptide-monoclonal antibody users)
OVERCOME (EU) migraine cohort | 0–3 HD/m (n = 13,759) | 4–7 HD/m (n = 4203) | 8–14 HD/m (n = 1730) | ≥ 15 HD/m (n = 1064) | Total (N = 20,756) |
Currentlyb using preventives,c n (%) | |||||
1 preventive | 943 (6.9) | 358 (8.5) | 171 (9.9) | 129 (12.1) | 1601 (7.7) |
2 preventives | 514 (3.7) | 188 (4.5) | 92 (5.3) | 68 (6.4) | 862 (4.2) |
≥ 3 preventives | 1475 (10.7) | 463 (11.0) | 186 (10.8) | 123 (11.6) | 2247 (10.8) |
Currentb preventive medication category,c n (%) – not mutually exclusive | |||||
Antiseizured | 1793 (13.0) | 604 (14.4) | 235 (13.6) | 171 (16.1) | 2803 (13.5) |
Antidepressante | 1903 (13.8) | 628 (14.9) | 282 (16.3) | 198 (18.6) | 3011 (14.5) |
Antihypertensivef | 2011 (14.6) | 649 (15.4) | 284 (16.4) | 180 (16.9) | 3124 (15.1) |
Onabotulinum toxin A | 322 (2.3) | 94 (2.2) | 45 (2.6) | 29 (2.7) | 490 (2.4) |
Survey respondents eligible for migraine preventive medicationa | N/A | 4–7 HD/m (n = 1458) | 8–14 HD/m (n = 792) | ≥ 15 HD/m (n = 499) | Total (N = 2749) |
Currentlyb using preventives,c n (%) | |||||
1 preventive | 173 (11.9) | 97 (12.2) | 79 (15.8) | 349 (12.7) | |
2 preventives | 73 (5.0) | 50 (6.3) | 41 (8.2) | 164 (6.0) | |
≥ 3 preventives | 104 (7.1) | 59 (7.4) | 41 (8.2) | 204 (7.4) | |
Currentb preventive medication category,c n (%) – not mutually exclusive | |||||
Antiseizured | 170 (11.7) | 99 (12.5) | 72 (14.4) | 341 (12.4) | |
Antidepressante | 201 (13.8) | 115 (14.5) | 99 (19.8) | 415 (15.1) | |
Antihypertensivef | 202 (13.9) | 121 (15.3) | 80 (16.0) | 403 (14.7) | |
Onabotulinum toxin A | 37 (2.5) | 18 (2.3) | 12 (2.4) | 67 (2.4) | |